Clinical Trial

Clinical Trial for Autologus NK Cells Alone or in Combination With Isatuximab as Maintenance for Multiple Myeloma

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Prospective, single center, randomized, open label, parallel group, 2-arm study assessing the clinical benefit in term of enhancement of overall response rate of Isatuximab in combination with CellProtect as compared to Isatuximab for the treatment of patients with newly diagnosed multiple myeloma who are eligible for stem cell transplantation (SCT) as maintenance after SCT.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2020-09-16; most recent amendment 2023-10-09.
Status change: Active, Not Recruiting → Recruiting 2023-08-15
Status change: Recruiting → Active, Not Recruiting 2023-02-14
Status change: Not Yet Recruiting → Recruiting 2021-11-29
Trial Details
NCT Number NCT04558931
Lead Sponsor Karolinska Institutet
Collaborators: Sanofi, XNK Therapeutics AB, Sweden
Conditions Multiple Myeloma
Enrollment 62 participants
Start Date 2021-06-02
Primary Completion 2027-12-31 (estimated)
Study Completion 2032-12-31 (estimated)
Updated on ClinicalTrials.gov 2023-10-11